Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)Takashi Seto, Kazuhiko Nakagawa, Haruyasu Murakami et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 50
LBA55 WJOG @Be study: A phase II study of atezolizumab (atez) with bevacizumab (bev) for non-squamous (sq) non-small cell lung cancer (NSCLC) with high PD-L1 expressionTakashi Seto, Kazuhiko Nakagawa, Kaname Nosaki et al.|Annals of Oncology|2020Cited by 7
Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 studyAkito Hata, Nobuyuki Yamamoto, Taira Ninomaru et al.|The Lancet Oncology|2025Cited by 5